Tag Archives: viekirax

February, 2016

26 February
AbbVie Announces Positive CHMP Opinion for Viekirax without Ribavirin in HCV

NORTH CHICAGO, Ill., Feb. 26, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for the use of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without …
Share

16 January
AbbVie’s Hepatitis C Drug Wins EC Approval

European regulators have approved AbbVie’s all-oral, interferon-free hepatitis C drug. The company announced today that the European Commission (EC) has granted marketing authorizations for Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for treatment with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 …
Share